Schwab Charles Investment Management Inc. increased its position in shares of Radius Health Inc (NASDAQ:RDUS) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 182,575 shares of the biopharmaceutical company’s stock after acquiring an additional 1,674 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.41% of Radius Health worth $5,801,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of the company. TimesSquare Capital Management LLC lifted its stake in shares of Radius Health by 184.6% during the third quarter. TimesSquare Capital Management LLC now owns 1,610,365 shares of the biopharmaceutical company’s stock valued at $62,080,000 after acquiring an additional 1,044,615 shares during the period. Orbimed Advisors LLC lifted its stake in Radius Health by 59.5% in the third quarter. Orbimed Advisors LLC now owns 1,122,800 shares of the biopharmaceutical company’s stock valued at $43,284,000 after buying an additional 418,700 shares during the period. Point72 Asset Management L.P. acquired a new position in Radius Health in the third quarter valued at about $17,236,000. DekaBank Deutsche Girozentrale lifted its stake in Radius Health by 45.9% in the third quarter. DekaBank Deutsche Girozentrale now owns 95,300 shares of the biopharmaceutical company’s stock valued at $3,472,000 after buying an additional 30,000 shares during the period. Finally, Sei Investments Co. lifted its stake in Radius Health by 2,302.7% in the third quarter. Sei Investments Co. now owns 76,407 shares of the biopharmaceutical company’s stock valued at $2,945,000 after buying an additional 73,227 shares during the period.
In related news, major shareholder Growth N. V. Biotech purchased 75,000 shares of Radius Health stock in a transaction that occurred on Friday, February 9th. The stock was purchased at an average cost of $34.38 per share, with a total value of $2,578,500.00. Following the completion of the transaction, the insider now owns 5,773,799 shares of the company’s stock, valued at approximately $198,503,209.62. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Growth N. V. Biotech purchased 80,000 shares of Radius Health stock in a transaction that occurred on Friday, March 2nd. The shares were bought at an average cost of $32.52 per share, with a total value of $2,601,600.00. Following the completion of the transaction, the insider now directly owns 5,853,799 shares of the company’s stock, valued at approximately $190,365,543.48. The disclosure for this purchase can be found here. 15.00% of the stock is currently owned by company insiders.
Radius Health Inc (RDUS) opened at $35.30 on Wednesday. The company has a current ratio of 5.04, a quick ratio of 4.96 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $1,560.00, a PE ratio of -6.09 and a beta of 1.19. Radius Health Inc has a fifty-two week low of $24.66 and a fifty-two week high of $49.16.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.43) by ($0.16). The company had revenue of $7.66 million during the quarter, compared to analyst estimates of $7.37 million. The business’s quarterly revenue was up 666.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.22) EPS. analysts anticipate that Radius Health Inc will post -5.05 EPS for the current year.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health Inc (NASDAQ:RDUS).
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.